AIGH Capital Management LLC Buys Shares of 654,115 Inovio Pharmaceuticals, Inc. (NASDAQ:INO)

AIGH Capital Management LLC acquired a new position in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 654,115 shares of the biopharmaceutical company’s stock, valued at approximately $1,197,000. Inovio Pharmaceuticals comprises 0.4% of AIGH Capital Management LLC’s portfolio, making the stock its 28th biggest holding. AIGH Capital Management LLC owned 2.51% of Inovio Pharmaceuticals at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in INO. BNP Paribas Financial Markets lifted its position in shares of Inovio Pharmaceuticals by 177.0% during the third quarter. BNP Paribas Financial Markets now owns 5,681 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 3,630 shares in the last quarter. MetLife Investment Management LLC lifted its holdings in Inovio Pharmaceuticals by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 15,167 shares of the biopharmaceutical company’s stock worth $88,000 after buying an additional 8,546 shares in the last quarter. Atom Investors LP purchased a new position in Inovio Pharmaceuticals in the 3rd quarter valued at approximately $103,000. FMR LLC grew its stake in shares of Inovio Pharmaceuticals by 370.1% in the third quarter. FMR LLC now owns 27,261 shares of the biopharmaceutical company’s stock worth $158,000 after acquiring an additional 21,462 shares in the last quarter. Finally, Barclays PLC increased its position in shares of Inovio Pharmaceuticals by 282.6% during the third quarter. Barclays PLC now owns 34,003 shares of the biopharmaceutical company’s stock worth $197,000 after acquiring an additional 25,116 shares during the period. Hedge funds and other institutional investors own 26.79% of the company’s stock.

Inovio Pharmaceuticals Stock Performance

Shares of NASDAQ INO opened at $1.73 on Friday. The stock’s 50-day simple moving average is $2.03 and its 200-day simple moving average is $3.53. The firm has a market capitalization of $45.15 million, a PE ratio of -0.43 and a beta of 0.92. Inovio Pharmaceuticals, Inc. has a fifty-two week low of $1.68 and a fifty-two week high of $14.75.

Inovio Pharmaceuticals (NASDAQ:INO) last released its quarterly earnings data on Tuesday, March 18th. The biopharmaceutical company reported ($0.69) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.18. The company had revenue of $0.12 million for the quarter, compared to analyst estimates of $0.03 million. On average, sell-side analysts forecast that Inovio Pharmaceuticals, Inc. will post -4.23 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently commented on INO shares. Royal Bank of Canada lowered their target price on Inovio Pharmaceuticals from $6.00 to $5.00 and set a “sector perform” rating for the company in a research note on Wednesday, March 19th. HC Wainwright reissued a “neutral” rating and set a $3.00 price objective on shares of Inovio Pharmaceuticals in a research report on Wednesday, March 19th. StockNews.com raised shares of Inovio Pharmaceuticals to a “sell” rating in a report on Friday, March 21st. Finally, JMP Securities reiterated a “market outperform” rating and set a $18.00 price target on shares of Inovio Pharmaceuticals in a report on Friday, January 10th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $12.20.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.